Țară: Canada
Limbă: engleză
Sursă: Health Canada
TRANEXAMIC ACID
JAMP PHARMA CORPORATION
B02AA02
TRANEXAMIC ACID
100MG
SOLUTION
TRANEXAMIC ACID 100MG
INTRAVENOUS
15G/50G
Prescription
HEMOSTATICS
Active ingredient group (AIG) number: 0114760002; AHFS:
APPROVED
2020-03-17
_ Tranexamic Acid Injection (tranexamic acid) _Page 1 of 24 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR TRANEXAMIC ACID INJECTION Tranexamic acid injection Solution, 100 mg / mL, Intravenous House Standard Antifibrinolytic agent JAMP Pharma Corporation 1310 rue Nobel Boucherville Quebec J4B 5H3, Canada Date of Initial Authorization: March 16, 2020 Date of Revision: November 28, 2022 Submission Control Number: 265633 _ Tranexamic Acid Injection (tranexamic acid) _Page 2 of 24 RECENT MAJOR LABEL CHANGES 2 CONTRAINDICATIONS 11/2022 4 DOSAGE AND ADMINISTRATION, 4.4 Administration 11/2022 7 WARNINGS AND PRECAUTIONS 11/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES .................................................................................................. 2 TABLE OF CONTENTS ..................................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION .......................................................................... 4 1 INDICATIONS ...................................................................................................................... 4 1.1 Pediatrics ....................................................................................................................... 4 1.2 Geriatrics .................................................................................................................. 4 2 CONTRAINDICATIONS ........................................................................................................ 4 4 DOSAGE AND ADMINISTRATION....................................................................................... 4 4.1 Dosing Considerations .............................................................................................. 4 4.2 Recommended Dose and Dosage Adjustment ......................................................... 5 4.3 Reconstitution ................. Citiți documentul complet